1
|
Wijetunga NA, Imber BS, Caravelli JF, Mikhaeel NG, Yahalom J. A picture is worth a thousand words: a history of diagnostic imaging for lymphoma. Br J Radiol 2021; 94:20210285. [PMID: 34111961 DOI: 10.1259/bjr.20210285] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
The journey from early drawings of Thomas Hodgkin's patients to deep learning with radiomics in lymphoma has taken nearly 200 years, and in many ways, it parallels the journey of medicine. By tracing the history of imaging in clinical lymphoma practice, we can better understand the motivations for current imaging practices. The earliest imaging modalities of the 2D era each had varied, site-dependent sensitivity, and the improved accuracy of imaging studies allowed new diagnostic and therapeutic techniques. First, we review the initial imaging technologies that were applied to understand lymphoma spread and achieve practical guidance for the earliest lymphoma treatments. Next, in the 3D era, we describe how anatomical imaging advances replaced and complemented conventional modalities. Afterward, we discuss how the PET era scans were used to understand response of tumors to treatment and risk stratification. Finally, we discuss the emergence of radiomics as a promising area of research in personalized medicine. We are now able to identify involved lymph nodes and body sites both before and after treatment to offer patients improved treatment outcomes. As imaging methods continue to improve sensitivity, we will be able to use personalized medicine approaches to give targeted and highly focused therapies at even earlier time points, and ideally, we can obtain long-term disease control and cures for lymphomas.
Collapse
Affiliation(s)
- N Ari Wijetunga
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Brandon Stuart Imber
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - James F Caravelli
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - N George Mikhaeel
- Department of Clinical Oncology, Guy's and St. Thomas' Hospital, London, UK
| | - Joachim Yahalom
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| |
Collapse
|
2
|
Steffanoni S, Ghielmini M, Moccia A. Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options. Expert Rev Anticancer Ther 2015; 15:1337-49. [DOI: 10.1586/14737140.2015.1092386] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
3
|
|
4
|
Buske C, Gisselbrecht C, Gribben J, Letai T, Mclaughlin P, Wilson W. Refining the treatment of follicular lymphoma. Leuk Lymphoma 2009; 49 Suppl 1:18-26. [DOI: 10.1080/10428190802311409] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
5
|
Kelley T, Beck R, Absi A, Jin T, Pohlman B, Hsi E. Biologic predictors in follicular lymphoma: Importance of markers of immune response. Leuk Lymphoma 2009; 48:2403-11. [DOI: 10.1080/10428190701665954] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
6
|
Long-Term Outcome and Prognostic Factors in Early-Stage Nodal Low-Grade Non-Hodgkin’s Lymphomas Treated with Radiation Therapy. Strahlenther Onkol 2009; 185:288-95. [DOI: 10.1007/s00066-009-1937-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2008] [Accepted: 02/12/2009] [Indexed: 01/29/2023]
|
7
|
Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, Rogers ES, Hainsworth JD, Wong EK, Vose JM, Zelenetz AD, Link BK. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009; 27:1202-8. [PMID: 19204203 PMCID: PMC2738614 DOI: 10.1200/jco.2008.18.1495] [Citation(s) in RCA: 233] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2008] [Accepted: 11/19/2008] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large prospective cohort study to identify current demographics and patterns of care of FL in the United States. PATIENTS AND METHODS The National LymphoCare Study is a multicenter, longitudinal, observational study designed to collect information on treatment regimens and outcomes for patients with newly diagnosed FL in the United States. Patients were enrolled between 2004 and 2007. There is no study-specific prescribed treatment regimen or intervention. RESULTS Two thousand seven hundred twenty-eight subjects were enrolled at 265 sites, including the 80% of patients enrolled from nonacademic sites. Using the Follicular Lymphoma International Prognostic Index (FLIPI), three distinct groups independent of histologic grade could be defined. Initial therapeutic strategy was: observation, 17.7%; rituximab monotherapy, 13.9%; clinical trial 6.1%; radiation therapy, 5.6%; chemotherapy only, 3.2%; chemotherapy plus rituximab, 51.9%. Chemotherapy plus rituximab regimens were: rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone, 55.0%; rituximab plus cyclophosphamide, vincristine, and prednisone, 23.1%; rituximab plus fludarabine based, 15.5%; other, 6.4%. The choice to initiate therapy rather than observe was associated with age, FLIPI, stage, and grade (P < .01). Significant differences in treatment (P < .01) across regions of the United States were noted. Contrary to practice guidelines, treatment of stage I FL frequently omits radiation therapy. CONCLUSION Widely disparate therapeutic approaches are utilized for FL. Initial therapy is deferred in a small subset of patients. There is no single standard of care for the treatment of de novo FL, although antibody use is ubiquitous when therapy is initiated. These disparate approaches to the initial care of patients with FL render a heterogeneous group of patients at relapse.
Collapse
Affiliation(s)
- Jonathan W. Friedberg
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Michael D. Taylor
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - James R. Cerhan
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Christopher R. Flowers
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Hildy Dillon
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Charles M. Farber
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Eric S. Rogers
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - John D. Hainsworth
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Elaine K. Wong
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Julie M. Vose
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Andrew D. Zelenetz
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Brian K. Link
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| |
Collapse
|
8
|
Vitolo U, Ferreri AJM, Montoto S. Follicular lymphomas. Crit Rev Oncol Hematol 2008; 66:248-61. [PMID: 18359244 DOI: 10.1016/j.critrevonc.2008.01.014] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2007] [Revised: 01/01/2008] [Accepted: 01/31/2008] [Indexed: 10/22/2022] Open
Abstract
Follicular lymphomas constitute approximately 30% of all non-Hodgkin lymphomas. These lymphomas are characterized by at least partially follicular growth pattern, but diffuse areas may be present. The proportions of follicular or diffuse areas vary also from case to case, which seems to be associated with prognosis. Follicular lymphomas should not be divided into distinct subtypes, but rather shows a continuous gradation in the number of large cells. On the bases of this grading, three groups have been defined: grades 1-3. There is a consensus that grade 3 follicular lymphomas, namely grade 3b, should be discriminated from lower-grade cases. The cells of follicular lymphomas express surface immunoglobulin, more frequently IgM+/-IgD>IgG>IgA, B-cell-associated antigens, CD10+/-; they are CD5-, CD23-/+, CD43-, and CD11c-. Follicular lymphomas express bcl-2 proteins, which is useful in distinguishing reactive from neoplastic follicles. t(14;18) is present in 70-95% of follicular lymphomas, involving rearrangement of bcl-2 gene. Clinical behavior of follicular lymphomas is heterogeneous and differs according to the histologic grade and extension of disease. Moreover, the evaluation of these malignancies is conditioned by therapeutic decision, which is also determined by main prognostic factors. The International Prognostic Index for aggressive lymphomas is not optimal for follicular lymphomas. Conversely, the Italian Lymphoma Intergroup Index and, more recently, the Follicular Lymphoma International Prognostic Index (FLIPI), designed in pre-rituximab era, seem to correlate well with outcome. Several active therapeutic approaches from the "wait and watch" strategy to the allogeneic transplantation are available for management of patients with follicular lymphoma. Therapeutic decision is mostly conditioned by patient's characteristics, stage, histologic grade, tumor burden, and risk-predicting factors.
Collapse
Affiliation(s)
- Umberto Vitolo
- Hematology Unit, Azienda Ospedaliera S. Giovanni Battista Molinette, Turin, Italy
| | | | | |
Collapse
|
9
|
Dickinson M, Wotherspoon A, Cunningham D. Sub-clinical dissemination of follicular lymphoma in normal sized lymph nodes may not be detected by radiologic staging: a case of disseminated follicular lymphoma detected in nodal clearance as part of therapy for cutaneous melanoma. Leuk Lymphoma 2006; 47:553-6. [PMID: 16396780 DOI: 10.1080/10428190500305596] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Patients with localized follicular lymphoma are potentially curable; however, the failure rate for local treatment suggests that a proportion of apparently localized disease is being under-staged. We report a case of incidentally diagnosed follicular lymphoma found in association with a stage II malignant melanoma, with immunohistochemical evidence of disseminated lymphoma in radiologically and clinically benign regional lymph nodes. This case provides some evidence to the cause of treatment failure in patients with clinically localized follicular lymphoma, and is a histologically proven example of the association between melanoma and lymphoma.
Collapse
|
10
|
Guadagnolo BA, Li S, Neuberg D, Ng A, Hua L, Silver B, Stevenson MA, Mauch P. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2005; 64:928-34. [PMID: 16243446 DOI: 10.1016/j.ijrobp.2005.08.010] [Citation(s) in RCA: 113] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2005] [Revised: 08/10/2005] [Accepted: 08/11/2005] [Indexed: 01/02/2023]
Abstract
PURPOSE To analyze long-term outcomes and causes of death in patients receiving radiation therapy (RT) for localized, low-grade follicular lymphoma. METHODS AND MATERIALS Between 1972 and 2000, 106 patients with Stage I-II, Grade 1-2 follicular lymphoma received RT alone or radiation and chemotherapy (RT/CT). Seventy-four percent had Stage I, and 26% had Stage II disease. Seventy-six percent received RT alone, and 24% received combined RT/CT. Second malignancy rates were compared with an age- and sex-matched population. RESULTS Median follow-up was 12 years. Median survival time was 19 years. The 5-, 10-, and 15-year overall survival (OS) rates were 93%, 75%, and 62%, respectively. Age > or = 60 was the only significant adverse prognostic factor with respect to OS. There were 35 deaths, 20 of which were attributable to lymphoma. Freedom from treatment failure (FFTF) rates at 5, 10, and 15 years were 72%, 46%, and 39%, respectively. Forty-seven patients (48%) relapsed. Tumor size > 3 cm was the only significant adverse factor for FFTF. Observed incidence of second malignancy did not significantly exceed expected incidence. CONCLUSIONS Although patients with early-stage, low-grade follicular lymphoma have long median survival, the leading cause of death remains lymphoma. However, patients receiving RT do not have significantly elevated cumulative incidence of second malignancy.
Collapse
MESH Headings
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Analysis of Variance
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Combined Modality Therapy
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/mortality
- Lymphoma, Follicular/pathology
- Lymphoma, Follicular/radiotherapy
- Lymphoma, Non-Hodgkin/drug therapy
- Lymphoma, Non-Hodgkin/mortality
- Lymphoma, Non-Hodgkin/pathology
- Lymphoma, Non-Hodgkin/radiotherapy
- Male
- Middle Aged
- Mortality/trends
- Neoplasm Staging
- Neoplasms, Second Primary/epidemiology
- Treatment Outcome
Collapse
Affiliation(s)
- Beverly A Guadagnolo
- Joint Center for Radiation Therapy/Harvard Radiation Oncology Residency Program, Boston, MA, USA.
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Ha CS, Lee MS, McLaughlin P, Tucker SL, Wilder RB, Cox JD, Cabanillas F. Molecular response of follicular lymphoma to cyclophosphamide, doxorubicin, vincristine, prednisone C(H)OP or COP-based therapy as measured by polymerase chain reaction evidence of translocation (14;18)(q32;q21). Cancer J 2004; 10:49-53. [PMID: 15000495 DOI: 10.1097/00130404-200401000-00010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE Existing data suggest that conventional C(H)OP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen may not be intensive enough to achieve molecular response, as measured by polymerase chain reaction (PCR) evidence of translocation (14;18)(q32:q21) for follicular lymphoma. This study was undertaken to study the molecular response rate of follicular lymphoma to C(H)OP-based therapy and to analyze prognostic factors for molecular response. PATIENTS AND METHODS Twenty patients with pretreatment PCR evidence of t(14;18)(q32; q21) and at least one posttreatment PCR analysis after the initiation of the treatment with C(H)OP with or without radiation therapy constituted the basis for this analysis. The random effects logistic model was used to analyze the data. The following factors were investigated for their relationship to molecular response: gender, age, beta2-microglobulin, use of radiation therapy, Ann Arbor stage, and international Prognostic Index for malignant lymphoma. RESULTS Median follow-up was 56 months (range, 23-153 months). A total of 135 PCR results were available, 33 from bone marrow and 102 from peripheral blood. Overall, there was a clear and steady decreasing trend toward loss of PCR positivity with increasing time aftertreatment. By univariate analysis, stage > or = 3, stage = 4, International Prognostic Index > or = 2, and no radiation therapy were adverse factors for molecular response. On multivariate analysis, Ann Arbor stage IV and no radiation therapy were independent risk factors for PCR positivity, both for the peripheral blood data analyzed alone and for all data combined. DISCUSSION It is possible to achieve molecular response with C(H)OP with or without radiation therapy in patients with follicular lymphoma. Response rate depends on the Ann Arbor stage and radiation therapy.
Collapse
MESH Headings
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Chromosomes, Human, Pair 14/chemistry
- Chromosomes, Human, Pair 14/genetics
- Chromosomes, Human, Pair 18/chemistry
- Chromosomes, Human, Pair 18/genetics
- Cyclophosphamide/therapeutic use
- Doxorubicin/therapeutic use
- Evaluation Studies as Topic
- Female
- Follow-Up Studies
- Genes, bcl-2/genetics
- Humans
- Logistic Models
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/genetics
- Male
- Middle Aged
- Polymerase Chain Reaction
- Prednisone/therapeutic use
- Prognosis
- Radiotherapy, Adjuvant
- Translocation, Genetic/genetics
- Treatment Outcome
- Vincristine/therapeutic use
- beta 2-Microglobulin/blood
Collapse
Affiliation(s)
- Chul S Ha
- Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030, USA.
| | | | | | | | | | | | | |
Collapse
|
12
|
Guermazi A, Brice P, Hennequin C, Sarfati E. Lymphography: An Old Technique Retains Its Usefulness. Radiographics 2003; 23:1541-58; discussion 1559-60. [PMID: 14615563 DOI: 10.1148/rg.236035704] [Citation(s) in RCA: 111] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Conventional lymphography has long been the method of choice for imaging the lymphatic system. However, the number of lymphographic studies performed in oncology centers has declined markedly since the introduction of cross-sectional imaging techniques, especially computed tomography (CT). Therefore, levels of expertise in both performing lymphography and interpreting lymphograms are falling. The unique ability of lymphography to demonstrate derangements of the internal architecture of normal-sized lymph nodes can be valuable and makes it more accurate than CT in evaluation of some lymphomas (especially Hodgkin disease) and genitourinary malignancies. In fact, lymphography and CT are complementary rather than mutually exclusive techniques for the staging of some lymphomas and genitourinary malignancies. In addition, lymphography opacifies the lymphatic channels and therefore may be a valuable tool for detection of lymphatic fistulas or lymphatic leakage. Finally, lymphography helps guide subsequent therapy in patients with lymphomas, genitourinary malignancies, or disorders of lymphatic flow.
Collapse
Affiliation(s)
- Ali Guermazi
- Department of Radiology, Saint-Louis University Hospital AP-HP, Paris, France.
| | | | | | | |
Collapse
|
13
|
Abstract
Optimal management of patients with localized Waldeyer's ring (WR) lymphoma remains controversial due to the lack of randomized studies and heterogenous grouping of most reported series. In this retrospective study, we have evaluated the possible prognostic factors and treatment outcome of WR non-Hodgkin's lymphoma. Between December 1993 and February 2000, 32 patients with WR lymphoma, stage I (11 patients) and stage II (21 patients) were treated. There were 17 male patients and 15 female patients with a median age of 47 years. The distribution among different anatomical sites were as follows: tonsils in 16 (50%), nasopharynx in 10 (31%), base of tongue in 6 (19%). According to Working Formulation, 10 had high-grade, 17 intermediate grade, 3 low-grade, and 2 had unclassified lymphomas. Combined chemotherapy and radiotherapy was the primary modality of therapy for intermediate or high-grade lymphoma. Radiotherapy alone was employed only in low-grade WR lymphomas. Chemotherapy was median 6 courses of CHOP (cyclophosphamide, doxorubicin (Adriamycin), vincristine, and prednisolone) in 26 patients and CEOP (cyclophosphamide, doxorubicin, etoposide, and prednisone). Radiotherapy volume was involved field and the median dose was 40 Gy. Median follow-up is 40 months (ranged from 6-82 months). Overall survival and disease-free survival (DFS) rates at 3 years are 100% and 92%, respectively. Two patients developed recurrence, both salvaged with further chemotherapy. Only one patient died because of other reasons. International Prognostic Index score (<or=2 vs. >2) is found to be an important prognostic factor for DFS. The other significant prognostic factors for DFS are performance status and serum levels of alkaline phosphatase and lactate dehydrogenase. Our results suggest that combined chemotherapy and involved field radiotherapy is appropriate treatment for stage I-II WR lymphoma. International Prognostic Index is the strongest predictor for DFS.
Collapse
Affiliation(s)
- Murat Gurkaynak
- Department of Radiation Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey
| | | | | | | | | | | |
Collapse
|
14
|
Abstract
In the era of conventional alkylating agent-based chemotherapy, advanced stage indolent lymphoma has been considered incurable. The failure of our traditional therapies to cure these patients, coupled with the indolent course of the disease and the elderly population affected, has fostered a nihilistic attitude about the treatment of these diseases. Twenty years ago, in the absence of interesting alternatives to alkylating agents, judicious use and reuse of alkylators was perhaps the best we could do. There are now many reasons for optimism and excitement in the treatment of these diseases, including the availability of promising agents such as interferon-alpha, the nucleoside analogues, and rituximab. Radioimmunotherapy will also likely play a role in future therapy programs. Allogeneic stem cell transplantation is a high-risk approach that is not an option for all patients, but it has the potential to cure patients, even in the setting of relapse. Mini-allogeneic transplantation may permit an approach to allogeneic transplantation that is better tolerated than standard transplant strategies. In addition to these therapy options, biological insights have provided new options for monitoring patients. Molecular monitoring (polymerase chain reaction for bcl-2) is a stringent measure of short-term treatment efficacy, and one that correlates with durability of remission, i.e., it is a surrogate marker by which to judge treatment efficacy. There used to be a limited number of conventional treatment approaches, which consistently failed. The pendulum has swung. There are now many promising new options. It is time to plan and conduct trials that are geared for success.
Collapse
Affiliation(s)
- Peter McLaughlin
- University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
| |
Collapse
|
15
|
Wilder RB, Jones D, Tucker SL, Fuller LM, Ha CS, McLaughlin P, Hess MA, Cabanillas F, Cox JD. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51:1219-27. [PMID: 11728680 DOI: 10.1016/s0360-3016(01)01747-3] [Citation(s) in RCA: 130] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
PURPOSE To analyze the long-term results with radiotherapy (RT) for early-stage, low-grade follicular lymphomas. METHODS AND MATERIALS From 1960 to 1988, 80 patients with Stage I (n = 33) or II (n = 47), World Health Organization Grade 1 (n = 50) or 2 (n = 30) follicular lymphoma were treated with RT. The lymph nodes or spleen were involved in 97% of cases. The maximal tumor sizes ranged from 0.5 to 11.0 cm (median 2.0). The RT fields encompassed only the involved Ann Arbor nodal region (involved-field RT) in 9% of the patients. The fields also included 1-3 adjacent, grossly uninvolved nodal regions (regional RT) in 54% of patients but were smaller than mantle or whole abdominopelvic fields. Mantle or whole abdominopelvic fields encompassing up to 6 grossly uninvolved regions (extended-field RT) were used in the remaining 37% of patients. The total RT doses ranged from 26.2 to 50.0 Gy given in daily 1.0-3.0-Gy fractions. RESULTS The follow-up of the surviving patients ranged from 3.5 to 28.7 years (median 19.0). No recurrences were found >17.0 years after RT, with 13 patients free of disease at their last follow-up visit 17.6-25.0 years after treatment. In 58% of cases, death was not from follicular lymphoma. The 15-year local control rate was 100% for 44 lymphomas <3.0 cm treated with only 27.8-30.8 Gy (median 30.0 in 20 fractions). Progression-free survival was affected by the maximal tumor size at the start of RT (15-year rate 49% vs. 29% for lymphomas <3.0 cm vs. > or =3.0 cm, respectively, p = 0.04) and Ann Arbor stage (15-year rate 66% vs. 26% for Stages I and II, respectively, p = 0.006). Ann Arbor stage also affected the cause-specific survival (15-year rate 87% vs. 54% for Stages I and II, respectively, p = 0.01). No significant difference was found in overall survival between those treated with extended-field RT and those treated with involved-field RT or regional RT (15-year rate 49% and 40%, respectively, p = 0.51). The 15-year incidence rate of Grade 3 or greater late complications according to the Subjective, Objective, Management, and Analytical scale in patients treated with 26.2-30.8 Gy vs. 30.9-50.0 Gy was 0% and 6%, respectively. CONCLUSIONS RT can cure approximately one half of Stage I and one quarter of Stage II, World Health Organization Grade 1 or 2 follicular lymphomas. Follicular lymphomas <3.0 cm can be controlled locally with doses of 27.8-30.8 Gy, and there is a trend toward a higher incidence of late complications with doses of >30.8 Gy. Doses of 25-30 Gy delivered in 15-20 fractions should be examined prospectively in patients with follicular lymphomas of <3.0 cm.
Collapse
Affiliation(s)
- R B Wilder
- Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Takahashi S, Yotnda P, Rousseau RF, Mei Z, Smith S, Rill D, Younes A, Brenner MK. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther 2001; 8:378-87. [PMID: 11477458 DOI: 10.1038/sj.cgt.7700315] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The malignant B cells of non-Hodgkin's lymphoma (B-NHL cells) express peptides derived from tumor-specific antigens such as immunoglobulin idiotypes, and also express major histocompatibility complex antigens. However, they do not express co-stimulatory molecules, which likely contributes to their protection from host antitumor immunity. To stimulate NHL-specific immune responses, we attempted to transfer the human CD40 ligand (hCD40L) gene to B-NHL cells and enhance their co-stimulatory potential. We found that an adenoviral vector encoding human CD40L (AdhCD40L) was ineffective at transducing B-NHL cells because these cells lack the coxsackievirus B-adenovirus receptor and alpha(v) integrins. However, preculture of the B-NHL cells with the human embryonic lung fibroblast line, MRC-5, significantly up-regulated expression of integrin alpha(v)beta 3 and markedly increased their susceptibility to adenoviral vector transduction. After prestimulation, transduction with AdhCD40L increased CD40L expression on B-NHL cells from 1.3+/-0.2% to 40.8+/-11.9%. Transduction of control adenoviral vector had no effect. Expression of transgenic human CD40L on these CD40-positive cells was in turn associated with up-regulation of other co-stimulatory molecules including B7-1/-2. Transduced B-NHL cells were now able to stimulate DNA synthesis of autologous T cells. However, the stimulated T cells were unable to recognize unmodified lymphoma cells, a requirement for an effective tumor vaccine. Based on previous results in an animal model, we determined the effects of combined use of B-NHL cells transduced with AdhCD40L and AdhIL2 vectors. The combination enhanced initial T-cell activation and generated autologous T cells capable of specifically recognizing and killing parental (unmodified) B-NHL cells via major histocompatibility complex--restricted cytotoxic T lymphocytes. These findings suggest that the combination of CD40L and IL2 gene-modified B-NHL cells will induce a cytotoxic immune response in vivo directed against unmodified tumor cells.
Collapse
Affiliation(s)
- S Takahashi
- Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Soubeyran P, Debled M, Tchen N, Richaud P, Monnereau A, Bonichon F, Eghbali H. Follicular lymphomas--a review of treatment modalities. Crit Rev Oncol Hematol 2000; 35:13-32. [PMID: 10863149 DOI: 10.1016/s1040-8428(00)00066-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
Follicular lymphoma is the most common low-grade non Hodgkin's lymphoma and represent an homogeneous entity as defined by pathological, molecular and clinical data. This indolent disease is characterised by a slow growth pattern with possible spontaneous regression, is often disseminated but remains incurable with available treatments when disseminated. For localised stages, involved field radiotherapy remains the standard choice but other approaches remain to be investigated. In advanced disease, chemotherapy has been demonstrated to produce high response rates but recent trials with new treatment strategies including interferon and monoclonal antibodies may improve the current situation. In this article, we will review treatment of follicular lymphomas, specially emphasising published phase III trials.
Collapse
Affiliation(s)
- P Soubeyran
- Institut Bergonié, Comprehensive Cancer Centre, 180, rue de Saint-Genès, F-33076 Cedex, Bordeaux, France.
| | | | | | | | | | | | | |
Collapse
|
18
|
Mahé MA, Bourdin S, Le Pourhiet-Le Mevel A, Moreau P, Campion L, Hamidou M, Milpied N, Moreau A, Gaillard F, Harousseau JL, Cuillière JC. Salvage extended-field irradiation in follicular non-Hodgkin's lymphoma after failure of chemotherapy. Int J Radiat Oncol Biol Phys 2000; 47:735-8. [PMID: 10837958 DOI: 10.1016/s0360-3016(00)00481-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
PURPOSE To evaluate the efficacy of total abdominopelvic (TAI) and total body irradiation (TBI) in heavily pretreated follicular non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS From 1983 to 1998, 34 patients received TAI (n = 22) or TBI (n = 12). All had Stage III or IV, Class B, C, D NHL in the working formulation and failed after receiving 1-5 regimens of chemotherapy. TAI was given at 20 Gy over a 3-week period. TBI was delivered in two successive half-body irradiations of 15 Gy over a 2-week period with a 4-week interval between each. RESULTS Mean follow-up from TAI or TBI was 120 months (range, 6-180). Seventy-six percent of patients achieved complete response and 24% partial response. Median survival was 62 months, 5-year and 10-year overall survival was 59% and 41%, and disease-free survival was 56% and 30%, respectively. Grade III or IV toxicity was gastrointestinal in 38% of patients and hematologic in 30%. No toxic death or delayed complications were observed. CONCLUSION Extended-field irradiation is feasible and efficient after failure of chemotherapy in follicular NHL.
Collapse
Affiliation(s)
- M a Mahé
- Centre René Gauducheau, Cedex, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Sapunar F, Catovsky D, Wotherspoon A, Matutes E. Follicular lymphoma. A series of 11 patients with minimal or no treatment and long survival. Leuk Lymphoma 2000; 37:163-7. [PMID: 10721781 DOI: 10.3109/10428190009057640] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Follicular lymphoma is the commonest low-grade lymphoma. Its indolent nature even in advanced stages and the failure of conservative or aggressive treatments to achieve a cure have questioned the need for immediate treatment. Eleven patients with follicular lymphoma who had minimal or no treatment were retrospectively reviewed. Median age was 44 years. Staging was: I (4), III (6) and IV (1). Eight were confirmed to have follicular lymphoma of whom six did not receive treatment at presentation. Four of these patients remain in remission after 14 to 30 years of follow-up and the other two have relapsed after 10 and 13 years of follow-up, respectively. Two patients who were treated at diagnosis remained disease free for 18 years. Three patients had diffuse large cell lymphoma on review. They received no treatment, radiotherapy or chemotherapy and have been in remission for 36, 14 and 23 years respectively. The overall survival is 58% at 30 years, and median survival has not been reached for the whole group. Observation seems to be a valid alternative to treatment in patients with stages I to III until signs of progression.
Collapse
Affiliation(s)
- F Sapunar
- Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
| | | | | | | |
Collapse
|
20
|
|
21
|
Ha CS, Tucker SL, Blanco AI, Cabanillas F, Cox JD. Salvage central lymphatic irradiation in follicular lymphomas following failure of chemotherapy: a feasibility study. Int J Radiat Oncol Biol Phys 1999; 45:1207-12. [PMID: 10613314 DOI: 10.1016/s0360-3016(99)00300-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
PURPOSE Management of follicular lymphoma after chemotherapy failure has been controversial and has ranged from watchful waiting to high-dose chemotherapy. High-dose chemotherapy with bone marrow reconstitution may produce clinical and molecular complete responses at the risk of serious morbidity and mortality. It has been previously reported that central lymphatic irradiation (CLI) can achieve long-term relapse-free survival in patients with Stage I, II, or III follicular lymphoma. Therefore, we investigated the feasibility of treating patients in whom front-line chemotherapy failed with salvage CLI instead of instituting more intensive chemotherapy. METHODS AND MATERIALS Salvage CLI with curative intent for patients with follicular lymphoma was started at The University of Texas M. D. Anderson Cancer Center in 1992. Eleven patients whose disease showed poor response to or relapsed after chemotherapy were managed with this approach. The median age of the patients was 61 years. Criteria for exclusion included bone marrow involvement or other evidence of Ann Arbor Stage IV disease at any time during the course of the disease. Overall survival and relapse-free survival were calculated from the first day of CLI. RESULTS Ten patients were alive at a median follow-up of 25 months (range 9-73 months). The treatment was well tolerated in general. Two patients could not complete CLI: one 75-year-old patient owing to prolonged platelet count depression and deterioration in general medical condition, and a 66-year-old patient because of exacerbation of preexisting pancytopenia and worsening of heart disease. Everyone who completed CLI remains in remission at the time of this report, except for one patient who had a relapse in the right lacrimal gland at 32 months. This patient was treated with local radiation therapy and is free of disease. Eventual recovery of the blood counts was observed for the patients who completed CLI. CONCLUSION These results demonstrate for the first time that with CLI, it is possible to achieve complete remission of acceptable quality in follicular lymphoma patients who experience a chemotherapy failure. The main toxicity is limited to transient depression in hematological profiles. The treatment is fairly well tolerated and seems to carry little risk compared with high-dose chemotherapy and bone marrow rescue. Salvage CLI may not necessarily compromise future treatment with chemotherapy, including autologous bone marrow or stem cell transplantation, because the patients' blood counts recover.
Collapse
Affiliation(s)
- C S Ha
- Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA.
| | | | | | | | | |
Collapse
|
22
|
Logsdon MD, Meyn RE, Besa PC, Pugh WC, Stephens LC, Peters LJ, Milas L, Cox JD, Cabanillas F, Brisbay S, Andersen M, McDonnell TJ. Apoptosis and the Bcl-2 gene family -- patterns of expression and prognostic value in stage I and II follicular center lymphoma. Int J Radiat Oncol Biol Phys 1999; 44:19-29. [PMID: 10219790 DOI: 10.1016/s0360-3016(98)00455-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
PURPOSE The prognostic significance of spontaneous levels of apoptosis and Bcl-2, Bax, and Bcl-x protein expression in follicular center lymphoma (FCL) is unknown. The objectives of this retrospective study were (1) to investigate the relationship between pretreatment apoptosis levels and long-term treatment outcome in patients with Stage I and II FCL; (2) to define the incidence and patterns of Bax and Bcl-x protein expression in human FC; and (3) to determine the relationship of Bcl-2, Bax, and Bcl-x expression with spontaneous apoptosis levels and clinical outcome in localized FCL. METHODS AND MATERIALS Between 1974 and 1988, 144 patients with Stage I or II FCL were treated. Hematoxylin and eosin (H & E) stained tissue sections of pretreatment specimens were retrieved for 96 patients. Treatment consisted of regional radiation therapy (XRT) for 25 patients, combined modality therapy (CMT) consisting of combination chemotherapy and XRT for 57 patients, and other treatments for 14 patients. Median follow-up for living patients was nearly 12 years. The apoptotic index (AI) was calculated by dividing the number of apoptotic cells by the total number of cells counted and multiplying by 100. Expression of Bcl-2, Bax, and Bcl-x proteins was assessed using immunohistochemistry. RESULTS The mean and median AI values for the entire group were 0.53 and 0.4, respectively (range: 0-5.2). The AI strongly correlated with cytologic grade, with mean AI values of 0.25 for grade 1, 0.56 for grade 2, and 0.84 for grade 3 (p < 0.0005; Kendall correlation). A positive correlation was present between grouped AI and grouped mitotic index (MI) (p = 0.014). For patients treated with CMT, an AI < 0.4 correlated with improved freedom from relapse (FFR) p = 0.0145) and overall survival (OS) (p = 0.0081). An AI < 0.4 did not correlate with clinical outcome for the entire cohort or for patients receiving XRT only. Staining of tumor follicles for the Bcl-2 protein was positive, variable, and negative in 73%, 15%, and 12% of cases, respectively. Positive staining of tumor follicles was observed in 96% of cases for both the Bax and Bcl-x proteins. Expression of Bcl-2, Bax, or Bcl-x did not correlate with AI or clinical outcome. CONCLUSION The level of spontaneous apoptosis in pretreatment specimens correlates with cytologic grade of FCL and is a significant predictor of FFR and OS for patients with localized FCL receiving CMT.
Collapse
Affiliation(s)
- M D Logsdon
- Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Ganem G, Thirion P. [Role of radiotherapy in the treatment of adult nodal non-Hodgkin's lymphoma]. Cancer Radiother 1999; 3:129-40. [PMID: 10230372 DOI: 10.1016/s1278-3218(99)80043-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
RADIOTHERAPY OF ADULT NODAL NON HODGKIN'S LYMPHOMA: The role of radiotherapy in the treatment of nodal non-Hodgkin's lymphoma has been modified by the introduction of efficient chemotherapy and the development of different pathological classifications. INTERMEDIATE GRADE OR HIGH GRADE LYMPHOMA: The recommended treatment of early-stage aggressive lymphomas is primarily a combination chemotherapy. The interest of adjuvant radiotherapy remains unclear and has to be established through large prospective trials. If radiation therapy has to be delivered, the historical results of exclusive radiation therapy showed that involved-fields and a dose of 35-40 Gy (daily fraction of 1.8 Gy, 5 days a week) are the optimal schedule. The interest of radiotherapy in the treatment of advanced-stage aggressive lymphoma is yet to be proven. Further studies had to stratify localized stages according to the factors of the International Prognostic Index. LOW-GRADE LYMPHOMA: For early-stage low-grade lymphoma, radiotherapy remains the standard treatment. However, the appropriate technique to use is controversial. Involved-field irradiation at a dose of 35 Gy seems to be the optimal schedule, providing a 10-year disease-free survival rate of 50% and no major toxicity. There is no standard indication of radiotherapy in the treatment advanced-stage low-grade lymphoma. RARE AND NEW ENTITY: For "new" nodal lymphoma's types, the indication of radiotherapy cannot be established (mantle-zone lymphoma, marginal zone B-cell lymphoma) or must take into account the natural history (Burkitt's lymphoma, peripheral T-cell lymphoma) and the sensibility to others therapeutic methods.
Collapse
Affiliation(s)
- G Ganem
- Centre Jean-Bernard, Le Mans
| | | |
Collapse
|
24
|
Oh YK, Ha CS, Samuels BI, Cabanillas F, Hess MA, Cox JD. Stages I-III follicular lymphoma: role of CT of the abdomen and pelvis in follow-up studies. Radiology 1999; 210:483-6. [PMID: 10207433 DOI: 10.1148/radiology.210.2.r99fe63483] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
PURPOSE To evaluate the efficiency of axial computed tomography (CT) in detecting relapses of stage I, II, or III follicular lymphoma. MATERIALS AND METHODS A total of 328 patients with previously untreated stage I, II, or III follicular lymphoma were treated between 1978 and 1994. Two hundred fifty-seven patients achieved complete response; 78 who relapsed form the basis of this study. Fifteen patients had stage I; 28, stage II; and 35, stage III disease. Fifteen patients underwent radiation therapy; 12, chemotherapy; and 51, radiation and chemotherapy. Medical records were reviewed to analyze the yield of abdominal and pelvic CT in detecting recurrence relative to the yield of standard clinical, hematologic, and imaging studies. A positive study was defined as one that led to or was abnormal at the diagnosis of recurrence. RESULTS The median follow-up was 101 months. Eleven relapses were detected only at abdominal, pelvic, or both abdominal and pelvic CT. CONCLUSION Fourteen percent (11 of 78) of the relapses were detected solely at abdominal and/or pelvic CT. Eleven (4.3%) of the 257 patients who achieved complete response benefited from abdominal and pelvic CT. The yield of the routine use of abdominal and pelvic CT in follow-up studies appears to be low for stages I-III follicular lymphoma.
Collapse
Affiliation(s)
- Y K Oh
- Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | |
Collapse
|
25
|
Mac Manus MP, Rainer Bowie CA, Hoppe RT. What is the prognosis for patients who relapse after primary radiation therapy for early-stage low-grade follicular lymphoma? Int J Radiat Oncol Biol Phys 1998; 42:365-71. [PMID: 9788417 DOI: 10.1016/s0360-3016(98)00233-8] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
PURPOSE To investigate the potential for long-term survival for patients who relapsed after primary radiation therapy (RT) for early-stage low-grade follicular lymphoma and to assess the relative importance of prognostic factors. METHODS AND MATERIALS Records were reviewed for 79 patients with stage I (n = 32) and II (n = 47) follicular small cleaved cell (fsc, n = 48) and follicular mixed small cleaved cell and large-cell (fmx, n = 31) lymphoma who relapsed after radical RT at Stanford University. Most patients had received doses of 35 to 45 Gy to involved (n = 30) or extended fields (n = 39) or total/subtotal lymphoid irradiation (n = 9). RESULTS Median time to relapse was 2 years. Most relapses were detected on history (30%) or physical examination (66%). Positive relapse investigations included lymphangiogram (n = 19), chest radiograph (n = 5), and bone marrow biopsy (n = 6). Known extent of relapsed disease was: stage I, n = 30; stage II, n = 26; stage III, n = 10; and stage IV, n = 8. Patients were managed with "watchful waiting" (37%), further RT (39%), chemotherapy [CT, (17%)], or RT + CT (5%). Actuarial survival rates after relapse at 5, 10, 15, and 20 years were 56%, 35%, 17%, and 17% respectively. Median survival was 5.3 years after relapse. Median survival for relapse stage I, II, III, and IV was 10.2, 5.5, 3.0, and 1.1 years respectively. Progression-free survival rates at 5, 10, 15, and 20 years after relapse were 44%, 22%, 22%, and 22% respectively. Factors associated with reduced survival were increasing age, increasing relapse stage, symptoms, histologic transformation and > or = 3 relapse sites. Survival was the same for initial management with "watchful waiting" or RT. CONCLUSION Approximately 20% of patients experienced prolonged survival after relapse. Younger, asymptomatic patients with stage I-II relapsed disease had the best outcome but results were inferior to those for newly diagnosed stage I-II disease.
Collapse
Affiliation(s)
- M P Mac Manus
- Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
| | | | | |
Collapse
|
26
|
Sack H, Hoederath A, Stuschke M, Bohndorf W, Makoski HB, Müller RP, Pötter R. [Radiotherapy of follicle center lymphoma. Results of a German multicenter and prospective study. Members of the Study Group "NHL-early stages"]. Strahlenther Onkol 1998; 174:178-85; discussion 186. [PMID: 9581177 DOI: 10.1007/bf03038523] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
PURPOSE Follicle centre lymphoma grade I, II (REAL) or centroblastic-centrocytic lymphoma (Kiel classification) present a well defined clinical entity from a clinical point of view. These lymphomas are not curable by chemotherapy in early or advanced stages. They are treated by radiation therapy in early stages, but up to now the curative potency of radiotherapy has not been confirmed by prospective clinical trials. PATIENTS AND METHODS Between January 1986 and August 1993 117 adults with follicle centre lymphoma were recruited from 24 institutions to enter the multicentric prospective, not randomised clinical trial. Patients with histologically proven nodal follicle centre lymphoma of stages I, II and limited III were included. They were treated by a standardised radiotherapy regimen, in stage I by extended field and in stages II and III by total nodal irradiation. Dose per fraction was 1.8 to 2.0 Gy, in the abdominal bath 1.5 Gy up to a total dose of 26 Gy in adjuvant situation and 36 Gy to enlarged lymphoma. RESULTS All patients developed a complete remission at the end of radiotherapy. Median follow-up is 68 months. Overall survival of all patients in 86 +/- 3% at 5 and 8 years. Stage adjusted survival at 5 and 8 years was 89% for stage I, 86% for stage II and 81% for III. Patients in stages I and II < 60 years had survival rates of 94% at 5 and 8 years, patients > 60 years 63% (p < 0.0001). Recurrence free survival of all patients is 70% at 5 and 60 +/- 5% at 8 years. The number of recurrences is high with 29% at 5 and 41% at 8 years. All recurrences were seen within 7 years. The probability of localised nodal in-field recurrences is 11% and 22% at 5 and 8 years, respectively. Adverse prognostic factors were identified by multivariate analysis: age > 60 years, treatment breaks > or = 7 days and dose deviations > 20% from prescribed doses. Acute side effects of extended field irradiation were moderate. CONCLUSIONS On the basis of these results radiotherapy is a potentially curative therapeutic approach in stages I, II and limited III of follicle centre lymphoma. The optimal technique is total lymphoid irradiation with doses of 30 Gy in the adjuvant situation and 40 to 44 Gy in enlarged lymphomas. The number of local recurrences leads to the assumption, that the extension of radiotherapy to the total lymphoid system might reduce their frequency.
Collapse
|
27
|
Stuschke M, Hoederath A, Sack H, Pötter R, Müller RP, Schulz U, Karstens J, Makoski HB. Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Study Group NHL-frühe Stadien. Cancer 1997; 80:2273-84. [PMID: 9404705 DOI: 10.1002/(sici)1097-0142(19971215)80:12<2273::aid-cncr9>3.0.co;2-v] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND A prospective multicenter trial was performed to evaluate survival, patterns of relapse, and toxicity for clinically staged patients with lymph node centroblastic-centrocytic (cb/cc) lymphomas in Stages I-IIIA after large extended field irradiation (EFI) or total central lymphatic irradiation (TCLI). METHODS Between January 1986 and August 1993, 117 adults with clinical Stage I-IIIA lymph node cb/cc lymphoma (Kiel classification) were recruited. Patients in Stages I or II with mediastinal, hilar, periaortic, iliac, or mesenteric involvement and in Stage IIIA received TCLI, whereas patients with more peripherally located cb/cc lymphomas were treated with EFI. TCLI and EFI were administered to a total dose of 26 gray (Gy) with 2 Gy per daily fraction, with the exception of the whole abdomen, which was irradiated to a total dose of 25.5 Gy with 1.5 Gy per fraction. A boost of 10 Gy with 2 Gy per fraction was administered to enlarged and involved lymph nodes at the start of radiotherapy. RESULTS Sixty, 40, and 17 patients had Stage I, II, and limited IIIA disease (no bulk and less than 6 involved lymph node regions), respectively. Overall survival was 86% at 5 and 7 years; median follow-up was 68 months. The probabilities of relapse at any site, recurrences in lymph nodes, and in-field lymph node recurrences after TCLI were 17% in Stage I; 56%, 43%, and 40% in Stage II, respectively; and 44%, 35%, and 35% in Stage IIIA, respectively. The risk of disseminated extralymphatic relapses was 9% at 7 years. The most important adverse prognostic factor for in-field lymph node recurrences was a deviation of >20% from the assigned total radiation dose. After EFI, patients in Stage I had a significantly lower risk of recurrences in adjuvant irradiated lymph node regions than in unirradiated lymph node regions. Acute toxicity of EFI and TCLI was moderate. CONCLUSIONS In-field lymph node recurrences remained the main risk after TCLI, and a deviation of >20% from the assigned radiation dose was the major risk factor for in-field recurrences. From these data, a total dose of 40-44 Gy in conventional fractionation for the treatment of macroscopic cb/cc lymphomas and 30 Gy for the treatment of subclinical disease is recommended. A randomized study comparing TCLI with EFI is now being organized by this group.
Collapse
Affiliation(s)
- M Stuschke
- Department of Radiotherapy, University of Essen, Germany
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Solal-Celigny P. Management of histologically indolent non-Hodgkin's lymphomas. BAILLIERE'S CLINICAL HAEMATOLOGY 1996; 9:669-87. [PMID: 9138612 DOI: 10.1016/s0950-3536(96)80048-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Histologically indolent lymphomas which represent 40-50% of all non-Hodgkin's lymphomas encompass small lymphocytic lymphomas, follicular lymphomas and other entities more recently described such as mantle cell and marginal zone lymphomas. Their management has benefited from new drugs such as interferon alpha the purine analogues and new treatment modalities especially autologous stem cell transplantation.
Collapse
MESH Headings
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukemia, Lymphocytic, Chronic, B-Cell/therapy
- Lymphoma, Follicular/pathology
- Lymphoma, Follicular/therapy
- Lymphoma, Non-Hodgkin/pathology
- Lymphoma, Non-Hodgkin/therapy
Collapse
Affiliation(s)
- P Solal-Celigny
- Department of Haematology, Centre J. Bernard, Le Mans, France
| |
Collapse
|